Fig. 6: Inhibitors targeting viral protease substrates reduce SARS-CoV-2 titres in A549-Ace2 cells. | Nature Communications

Fig. 6: Inhibitors targeting viral protease substrates reduce SARS-CoV-2 titres in A549-Ace2 cells.

From: Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential

Fig. 6: Inhibitors targeting viral protease substrates reduce SARS-CoV-2 titres in A549-Ace2 cells.

Sorafenib is a tyrosine kinase inhibitor previously shown to inhibit SARS-CoV-2 replication4. Bafetinib is a dual ABL/LYN inhibitor with off-target activity against SRC kinase. ML-7 and MLCK target myosin light chain kinase (MYLK/MLCK). Black circles and error bars represent mean and standard deviation. n = 3 biologically independent samples. Red circles indicate individual datapoints. The limit of detection in the plaque assay was calculated to be 40 PFU/mL (dotted line). PFU plaque-forming units.

Back to article page